ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.18, Zacks reports.
ArriVent BioPharma Price Performance
AVBP stock traded down $0.66 during midday trading on Thursday, reaching $21.81. The company's stock had a trading volume of 190,741 shares, compared to its average volume of 165,656. The business's 50-day simple moving average is $26.32 and its 200-day simple moving average is $27.12. ArriVent BioPharma has a 52 week low of $14.35 and a 52 week high of $36.37.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright upped their price target on ArriVent BioPharma from $36.00 to $39.00 and gave the company a "buy" rating in a research note on Wednesday, January 22nd.
Check Out Our Latest Analysis on ArriVent BioPharma
ArriVent BioPharma Company Profile
(
Get Free Report)
ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.
Read More
Before you consider ArriVent BioPharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ArriVent BioPharma wasn't on the list.
While ArriVent BioPharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
